MedTrace Logo

Tolerance to NeuroEPO in Parkinson Disease

NCT04110678 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2020-07-15

No results posted yet for this study

Summary

Treatment strategies in Parkinson's disease (PD) can improve a patient's quality of life but cannot stop the progression of PD. The investigators are looking for different alternatives that modify the natural course of the disease and recent research has demonstrated the neuroprotective properties of erythropoietin. In Cuba, the Center for Molecular Immunology (CIM) is a cutting edge scientific center where the recombinant form (EPOrh) and recombinant human erythropoietin with low sialic acid (NeuroEPO) are produced.

Conditions

  • Parkinson Disease

Interventions

DRUG

NeuroEPO

NeuroEPO \[CIMAB S.A, Havana, Cuba\]

Sponsors & Collaborators

  • Center of Molecular Immunology, Cuba

    collaborator OTHER

  • University of Electronic Science and Technology of China

    collaborator OTHER

  • International Center for Neurological Restoration, Cuba

    lead OTHER

Principal Investigators

  • Daniel E Amaro Gonzalez, PhD Eng · Centro Inmunologia Molecular CIM Havana Cuba

  • Teresita Rodríguez Obaya, PhD · Centro Immunologia Molecular CIM Havana Cuba

  • Iliana Sosa Teste, PhD · Centro Nacional Producción Animales de Laboratorio (CENPALAB) Cuba

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-01
Primary Completion
2016-02-11
Completion
2017-01-01

Countries

  • Cuba

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04110678 on ClinicalTrials.gov